November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
64 citations
,
January 1985 in “Clinical endocrinology” A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
6 citations
,
August 2024 in “Experimental Dermatology” Irisin can promote hair growth by activating a specific signaling pathway.
November 2018 in “Annals of oncology” A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
23 citations
,
September 2020 in “BMC Cancer” 5α-reductase inhibitors may lower the risk of death from bladder cancer.
56 citations
,
March 2003 in “Journal of Investigative Dermatology” 17β-estradiol can reduce inflammation in the skin.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
18 citations
,
October 2015 in “Journal of the European Academy of Dermatology and Venereology” Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
3 citations
,
January 2019 in “Indian Journal of Drugs in Dermatology” Certain cancer drugs can cause skin issues like rashes and itching.